Navigation Links
Oncolytics Biotech(R) Inc. Collaborators Present Positive Phase II Sarcoma Trial Results at CTOS Annual Meeting
Date:11/6/2009

ated in order to integrate the virus in the panoply of agents used for sarcoma treatment."

"These results are consistent with what we observed on an interim basis when we reported data on the first 16 patients back in June 2008," said Dr. Brad Thompson, President and CEO of Oncolytics. "It is encouraging that we are observing stable disease in a range of sarcomas and the clinical benefit is not isolated to any specific type."

A copy of the poster will be available on the Oncolytics website today.

About Oncolytics Biotech Inc.

Oncolytics is a Calgary-based biotechnology company focused on the development of oncolytic viruses as potential cancer therapeutics. Oncolytics' clinical program includes a variety of human trials including a Phase III trial in head and neck cancers using REOLYSIN, its proprietary formulation of the human reovirus. For further information about Oncolytics, please visit: www.oncolyticsbiotech.com.

This press release contains forward-looking statements, within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended. Forward-looking statements, including the implication of the materials presented at the CTOS meeting with respect to REOLYSIN; the Company's belief as to the potential of REOLYSIN as a cancer therapeutic; the Company's expectations as to the success of its research and development programs in 2009 and beyond, the Company's planned operations, the value of the additional patents and intellectual property; the Company's expectations related to the applications of the patented technology; the Company's expectations as to adequacy of its existing capital resources; the design, timing, success of planned clinical trial programs; and other statements related to anticipated developments in the Company's business and technologies involve known and unknown risks and uncertainties, which could cause the Company's actua
'/>"/>

SOURCE Oncolytics Biotech Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Oncolytics Biotech Inc. Announces Issuance of 23rd U.S. Patent
2. Oncolytics Biotech Inc. Reports Positive Interim Results of U.K. Phase Ia/Ib Combination REOLYSIN(R) and Radiation Clinical Trial
3. Media Advisory - Oncolytics Biotech Inc. to Present at BioPartnering Europe
4. Media Advisory - Oncolytics Biotech Inc. to Present at BIO InvestorForum 2007
5. Oncolytics Biotech Inc. Announces Approval for U.K. Clinical Trial Investigating REOLYSIN(R) in Combination with Cyclophosphamide
6. Oncolytics Biotech Inc. Collaborators to Present Positive Interim Results of U.K. Phase Ia/Ib Combination REOLYSIN(R) and Radiation Clinical Trial
7. Oncolytics Biotech Inc. Announces 2007 Third Quarter Results
8. Media Advisory - Oncolytics Biotech Inc. to Present at Acumen BioFin Rodman & Renshaw 9th Annual Healthcare Conference
9. Media Advisory - Oncolytics Biotech Inc. to Present at Toronto CFA Society
10. Oncolytics Biotech Inc. Announces Issuance of 24th U.S. Patent
11. Oncolytics Biotech Inc. to Present at Annual Vaccine Production Conference

Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/24/2009)...-FirstCall/--Sigma-AldrichCorporation(Nasdaq: SIAL...y,December1stat1:45PMGMTinLondon,7:45AMUS/CST.Inte...Internetavailableat http://inve s tor.sig m a...accessthisfile. ,, AboutSigma-Aldrich: Sigma...any.Itschemicalandbiochemicalproductsandkitsareuse...
(Date:11/24/2009)...-Asia/--ShanghaiBiolaxyannouncedthe,ChineseStateFo...stigationalnewdrugapplication(IND)foritsoralinsuli...treatdiabetes.ThisIND,approvalallowsBiolaxytoiniti...disordercharacteristicofhighbloodglucoseandpoor,me...veremicro-and,macro-vasculardiseases,lossofvision,...
(Date:11/24/2009)...re-FirstCall/--Shireplc(LSE:SHP,NASDAQ: SHPGY ),t...nouncedthatithassubmittedaMAAtotheEuropeanMedicine...lacementtherapyindevelopment,forthetreatmentofType...nforvelaglucerasealfathathasbeensubmitted,withprev... Basedonaglobalsupplyshortageofthecurrentlyapprove...
(Date:11/24/2009)... Abstracts Service (CAS), the global expert on che...ice is now the world,s leading producer of patent ... Japan,s patent office, the World Intellectual Pro...atent and Trademark Office (USPTO) for more than a...6, and exceeded Japan for the first time on a mont...
Breaking Biology Technology:Biolaxy Secures IND Approval for Oral Insulin 2Shire Submits European Marketing Authorization Application (MAA) for velaglucerase alfa for the Treatment of Type 1 Gaucher Disease 2Shire Submits European Marketing Authorization Application (MAA) for velaglucerase alfa for the Treatment of Type 1 Gaucher Disease 3China Leads All Nations in Publication of Chemical Patents According to CAS, the World's Most Authoritative Publisher of Chemical Information 2China Leads All Nations in Publication of Chemical Patents According to CAS, the World's Most Authoritative Publisher of Chemical Information 3
...been following the Abbott Laboratories story reg... the government of Thailand over patent protection...a relatively isolated tiff between a single drug c...ider this to be a central - if not the central... a few - myself included - regard this to be one o...
... In many ways, Promega Corp . has given Northwes...mpany. , ,Quiet to those outside the life-science ...s suburban Madison walls, it,s anything but silent...hus far, that innovation has produced about 200 pa...ding 130 new product innovations since 2002. , ,Th...
...Advanced Cell Technology , the California biotechn...overed a way to extract stem cells from human embr... expanded commercialization agreement with the Wi...ent grants the company the right to the commercial...ous human therapies. , ,Advanced Cell Technology, ...
Other Biology Technology:Abbott vs. Thailand has implications for innovation and access 2Abbott vs. Thailand has implications for innovation and access 3Abbott vs. Thailand has implications for innovation and access 4Abbott vs. Thailand has implications for innovation and access 5Abbott vs. Thailand has implications for innovation and access 6Abbott vs. Thailand has implications for innovation and access 7Promega Corporation: Wisconsin's quiet innovator 2Promega Corporation: Wisconsin's quiet innovator 3Promega Corporation: Wisconsin's quiet innovator 4Promega Corporation: Wisconsin's quiet innovator 5WARF expands license agreement with Advanced Cell Technology 2
(Date:11/25/2009)...sors recently received funding from the National S...icial to understanding the environment. The three ...assistant professor in the Department of Biologica...rate research projects. , His first project, tit...Functions from the Leaf to the Landscape," will ex...
(Date:11/24/2009)...t may help gut bacteria bind to the gastrointestin...roducers to identify strains that are likely to be... interact with cells lining the gut to have a bene...he gut they are more likely to stick around long e...uge from the Institute of Food Research. IFR is a...
(Date:11/24/2009)...crets of the earth,s history locked in its icy dep...e information on the environments that have been s...Now, a team of researchers from nine institutions ...0 million dollars by the National Science Foundati...lly. These scientists will drill through the West ...
Breaking Biology News(10 mins):Kent State University professors focus research on the environment with grants totaling $890,000 2A sticky solution for identifying effective probiotics 2LSU gets to the bottom of things -- in Antarctica 2MarketsandMarkets 3A Global Emerging Lighting Technologies Market Worth US 24112 2 Billion by 2014 55993 1MarketsandMarkets 3A Global Emerging Lighting Technologies Market Worth US 24112 2 Billion by 2014 55993 2MarketsandMarkets 3A Global Emerging Lighting Technologies Market Worth US 24112 2 Billion by 2014 55993 3Derma Sciences To Present at Rodman 26 Renshaws Eleventh Annual Healthcare Conference 55990 1Derma Sciences To Present at Rodman 26 Renshaws Eleventh Annual Healthcare Conference 55990 2Derma Sciences To Present at Rodman 26 Renshaws Eleventh Annual Healthcare Conference 55990 3NeurogesX to Present at Upcoming Fall Conferences 13797 1NeurogesX to Present at Upcoming Fall Conferences 13797 2NeurogesX to Present at Upcoming Fall Conferences 13797 3NeurogesX to Present at Upcoming Fall Conferences 13797 4
...Scientists at Washington University School of Medi... some of the bacteria that plague women with urina...uman bladder cells. , The finding confirms a cont...teria cause UTIs. Previously, most researchers ass...get into the bladder but do not invade the individ...
...ansmitters have consequences. They initiate events...e ability to move, to talk, to breathe, to think. ...right and sending proper signals downstream to mus...western University study reports that a mutation i...smitter in the nematode C. elegans causes an imbal...
...ndustry for the future in Sweden. However, to expl...demic and healthcare sectors will have to collabor...inical research. This is the conclusion of a joint...hnology (KTH), Karolinska Institutet and Karolinsk...record in the medtech field: Gambro, Getinge and E...
Other Biology News:Bacteria that cause urinary tract infections invade bladder cells 2Bacteria that cause urinary tract infections invade bladder cells 3Overexcited neurons not good for cell health 2Overexcited neurons not good for cell health 3New report finds great potential for Swedish medical technology 2
Rabbit Anti-alpha-N-Catenin Polyclonal Antibody, Unconjugated from Cell Signaling Technology
BioDoc-It System from UVP
AC1 Auto System, OptiChemi™ Camera from UVP
Analog thermal printer, Mitsubishi (115/230V) for BioDoc-It and VisiDoc-It Imaging Systems from UVP
Biology Products: